Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: LemurHouse who wrote (492)	3/22/2001 7:01:56 PM
From: software salesperson	Respond to of 656

andrew, according to the npf(www.psoriasis.org), there are 7 million psoriatics in the us, 10-30% of which have psoriatic arthritis.the number had been given as 10% for many, many years. don't know where the 30% came from. i would guess it's 10-15%. sales

To: LemurHouse who wrote (492)	3/22/2001 7:05:55 PM
From: LemurHouse	Respond to of 656

Bought at 10. Trading position only, leaving my LT position alone. Hope to sell tomorrow or next week on a rebound. Should be exciting! Long term I'm still above water, and very positive about the company's earnings prospects 12-18 months from now when full production comes on line. Quite a slide over the past few weeks down to around 20, before today's clinical trial results were disclosed and subsequent drop after hours. Hard to believe that the word wasn't getting around before hand. FWIW. AD

To: LemurHouse who wrote (492)	3/22/2001 8:07:52 PM
From: scaram(o)uche	Respond to of 656

I missed the beginning of the call as well. It's archived now, however, so..... at your leisure. In the release, they said 250K patients in U.S. for PA. Nuvance..... not particularly of interest to me at this cap. I realize that it's of interest to older shareholders, but..... until after hours today, I have never owned it. Or, I owned it years ago and have forgotten. I'm interested in (1) ENBREL for psoriasis (not just psoriatic arthritis), (2) CD40L, and (3) TRAIL/Apo2 ligand. They seemed sincere in still having an interest in the steroid-dependent population. Point made in a couple of different ways, that IL-4 may be of significantly greater interest in those receiving steroids. "The committee's recommendation was from lack of efficacy." That is great information at this market cap..... no downside (apparent) for the existing business, for a product that is pointing at the huge psoriasis market and for which there is apparently qualifying data for psoriatic arthritis. Last quarter annualized at $1 billion. $1.6B in cash, market cap of $5.4B at 17:00 EST. Down from 52 week high of $70/share. Positive news today for PA indication. This after hours reaction is, IMO, hilarious. Details given re. Rhode Island facility schedule. Guidance continues to be $750M for ENBREL this year. They're trying to squeeze more product out of current providers. Initial capacity at RI facility will be about $1 billion of product/year. There will be additional capacity at RI later, and AHP is considering options in Ireland. DO NOT MISS THE ARCHIVED CALL! Good luck, all!